<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35638376</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.</ArticleTitle><Pagination><StartPage>2810</StartPage><EndPage>2822</EndPage><MedlinePgn>2810-2822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15428</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies.</AbstractText><AbstractText Label="METHODS">Neurofilament light chain (NfL) and total tau (T-tau) were measured in the cerebrospinal fluid (CSF) and plasma in 41 patients with Guillain-Barr&#xe9; syndrome (GBS), 32 patients with chronic inflammatory demyelinating polyneuropathy (CIDP), 10 with paraproteinemia-related demyelinating polyneuropathy (PDN), and 8 with multifocal motor neuropathy (MMN), in comparison with 39 disease-free controls and 59 other controls. Outcome was measured with the GBS-disability score (GBS-ds) or Inflammatory Neuropathy Cause and Treatment (INCAT) disability score.</AbstractText><AbstractText Label="RESULTS">Neurofilament light chain levels in CSF and plasma were higher in GBS, CIDP, and PDN vs. disease-free controls. Patients with MMN had higher NfL levels in plasma vs. disease-free controls, but lower levels in CSF and plasma vs. patients with amyotrophic lateral sclerosis (ALS). T-tau levels in plasma were higher in GBS, CIDP, PDN, and MMN vs. all control groups. Neurofilament light chain levels in CSF and plasma in patients with GBS correlated with GBS-ds, as higher levels were associated with inability to run after 6 and 12&#x2009;months. NfL levels in CSF and plasma in CIDP did not correlate significantly with outcome.</AbstractText><AbstractText Label="CONCLUSIONS">Acute and chronic inflammatory neuropathies are associated with an increase in levels of NfL in CSF and plasma, but NfL is validated as a prognostic biomarker only in GBS. NfL could be used in differentiating patients with MMN from ALS. T-tau in plasma is a novel biomarker that could be used in a diagnostic assessment of patients with acute and chronic inflammatory polyneuropathies.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp;amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kmezic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8764-1940</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samuelsson</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upate</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Psychology, Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Psychology, Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Press</LastName><ForeName>Rayomand</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011115" MajorTopicYN="Y">Polyneuropathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020277" MajorTopicYN="Y">Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF and plasma</Keyword><Keyword MajorTopicYN="N">Guillain-Barr&#xe9; syndrome (GBS)</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">T-tau</Keyword><Keyword MajorTopicYN="N">chronic inflammatory demyelinating polyneuropathy (CIDP)</Keyword><Keyword MajorTopicYN="N">diagnosis and prognosis</Keyword><Keyword MajorTopicYN="N">multifocal motor neuropathy (MMN)</Keyword><Keyword MajorTopicYN="N">paraproteinemia-related demyelinating polyneuropathy (PDN)</Keyword></KeywordList><CoiStatement>Ivan Kmezic declares no conflicts of interest. Kristin Samuelsson has served on scientific advisory boards and/or as a consultant for Akcea Theurapeutics, Inc. and Alnylam Pharmaceuticals. Anja Finn declares no conflict of interest. Zane Upate declares no conflicts of interest. Kaj Blennow has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co&#x2010;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this article. Kaj Blennow is supported by the Swedish Research Council (#2017&#x2013;00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB&#x2010;201809&#x2010;2016615), the Swedish Alzheimer Foundation (#AF&#x2010;742881), Hj&#xe4;rnfonden, Sweden (#FO2017&#x2010;0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF&#x2010;agreement (#ALFGBG&#x2010;715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019&#x2010;466&#x2010;236), the National Institutes of Health (NIH), USA (grant #1R01AG068398&#x2013;01), and the Alzheimer's Association 2021 Zenith Award (ZEN&#x2010;21&#x2010;848495). Henrik Zetterberg has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures at symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co&#x2010;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018&#x2013;02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG&#x2010;720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809&#x2013;2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF&#x2010;21&#x2010;831376&#x2010;C, #ADSF&#x2010;21&#x2010;831381&#x2010;C, and #ADSF&#x2010;21&#x2010;831377&#x2010;C), the Olav Thon Foundation, the Erling&#x2010;Persson Family Foundation, Stiftelsen f&#xf6;r Gamla Tj&#xe4;narinnor, Hj&#xe4;rnfonden, Sweden (#FO2019&#x2010;0228), the European Union's Horizon 2020 research and innovation programme under the Marie Sk&#x142;odowska&#x2010;Curie grant agreement No. 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021&#x2010;00694), and the UK Dementia Research Institute at UCL. Rayomand Press declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>14</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35638376</ArticleId><ArticleId IdType="pmc">PMC9542418</ArticleId><ArticleId IdType="doi">10.1111/ene.15428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shahrizaila N, Lehmann HC, Satoshi Kuwabara S. Guillain&#x2010;Barr&#xe9; syndrome. Lancet. 2021;397(10280):1214&#x2010;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">33647239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784&#x2010;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">31076244</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftimov F, Lucke IM, Querol LA, et al. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2020;143(11):3214&#x2010;3224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719025</ArticleId><ArticleId IdType="pubmed">33155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomont P. The dazzling rise of neurofilaments: physiological functions and roles as biomarkers. Curr Opin Cell Bio. 2021;68:181&#x2010;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">33454158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870&#x2010;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, Hinds N, Murray NMF, et al. CSF neurofilament levels: a potential prognostic marker in Guillain&#x2010;Barr&#xe9; syndrome. Neurology. 2006;67(6):1071&#x2010;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000982</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson M, Sj&#xf6;gren M, Andersen O, et al. Neurofilament light protein levels in cerebrospinal fluid predict long&#x2010;term disability of Guillain&#x2010;Barr&#xe9; syndrome: a pilot study. Acta Neurol Scand. 2018;138(2):143&#x2010;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">29624650</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Lieverloo GGA, Wieske L, Verhamme C, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Sys. 2019;24(2):187&#x2010;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">30973667</ArticleId></ArticleIdList></Reference><Reference><Citation>Godelaine J, De Schaepdryver M, Bossuyt X, et al. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun. 2021;3(1):fcab018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7991223</ArticleId><ArticleId IdType="pubmed">33796853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n&#x2010;Aguilar L, Camps&#x2010;Renom P, Lleix&#xe0; C, et al. Serum neurofilament light chain predicts long&#x2010;term prognosis in Guillain&#x2010;Barr&#xe9; syndrome patients. J Neurol Neurosurg Psychiatry. 2021;92:70&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">33154183</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotto S, Farinazzo A, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23(3):174&#x2010;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">29974556</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133(5):665&#x2010;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390006</ArticleId><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Kaj Blennow K, Breteler MMB, et al. Alzheimer's disease. Lancet. 2016;388(10043):505&#x2010;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Brody DL, Kochanek PM, et al. Traumatic brain injuries. Nat Rev Dis Primers. 2016;2:16084.</Citation><ArticleIdList><ArticleId IdType="pubmed">27853132</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM, Kramer AO, Casey M, et al. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt&#x2010;Jakob disease. JAMA Neurol. 2019;76(8):969&#x2010;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6503575</ArticleId><ArticleId IdType="pubmed">31058916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein R, Chang B, Davies P, et al. A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids. J Neurotrauma. 2015;32(5):342&#x2010;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348038</ArticleId><ArticleId IdType="pubmed">25177776</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall J, M&#xf6;rtberg E, Provuncher GK, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation. 2013;84(3):351&#x2010;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">22885094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Takeda A, Shiga Y, Sato S, et al. CSF tau protein: a new prognostic marker for Guillain&#x2010;Barr&#xe9; syndrome. Neurology. 2006;67(8):1470&#x2010;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060576</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, Brettschneider J, Jin K, et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain&#x2010;Barr&#xe9; syndrome. Muscle Nerve. 2009;40(1):42&#x2010;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">19533642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XK, Zhang HL, Meng FH, et al. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain&#x2010;Barr&#xe9; syndrome. Neurol Sci. 2013;34(5):655&#x2010;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">22526766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Kojima Y, Ohmichi T, et al. Combined use of CSF NfL and CSF TDP&#x2010;43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6(12):2489&#x2010;2502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain&#x2010;Barr&#xe9; syndrome. Ann Neuro. 1990;27:S21&#x2010;S24.</Citation><ArticleIdList><ArticleId IdType="pubmed">2194422</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society &#x2010; first revision. Eur J Neurol. 2010;17(3):356&#x2010;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">20456730</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies . Report of a joint task force of the European federation of neurological societies and the peripheral nerve society&#x2010;&#x2010;first revision. J Peripher Nerv Syst. 2010;15(3):185&#x2010;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">21040140</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy . Report of a joint task force of the European federation of neurological societies and the peripheral nerve society&#x2010;&#x2010;first revision. J Peripher Nerv Syst. 2010;15(4):295&#x2010;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RA, Newsom&#x2010;Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750&#x2010;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">80682</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Koningsveld R, Schmitz PIM, Avander Mech&#xe9; FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain&#x2010;Barr&#xe9; syndrome: randomized trial. Lancet. 2004;363(9404):192&#x2010;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">14738791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195&#x2010;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, H&#xf6;glund K, Parnetti L, et al. A new enzyme&#x2010;linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer&#x2019;s Res Ther. 2018;10(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389166</ArticleId><ArticleId IdType="pubmed">29370869</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Schuck T, Schmidt ML, et al. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989;37(2):209&#x2010;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">2492045</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieff IS, Liem RK, Mellado W, et al. High molecular weight tau: preferential localization in the peripheral nervous system. J Cell Sci. 1991;100(Pt 1):55&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">1724450</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer I, Baas PW. Resurrecting the mysteries of Big tau. Trends Neurosci. 2020;43(7):493&#x2010;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999525</ArticleId><ArticleId IdType="pubmed">32434664</ArticleId></ArticleIdList></Reference><Reference><Citation>Day GS, Yarbrough MY, K&#xf6;rtvelyessy P, et al. Prospective quantification of CSF biomarkers in antibody&#x2010;mediated encephalitis. Neurology. 2021;96(20):e2546&#x2010;e2557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205475</ArticleId><ArticleId IdType="pubmed">33795390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, Smyth D, Lunn MP, et al. Fluid biomarkers for monitoring structural changes in polyneuropathies: their use in clinical practice and trials. Neurotherapeutics. 2021;18(4):2351&#x2010;2367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522180</ArticleId><ArticleId IdType="pubmed">34661878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman J, Dring A, Zetterberg H, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972001</ArticleId><ArticleId IdType="pubmed">27536708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barth&#xe9;lemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284&#x2010;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>